Complementation of Monoclonal Antibodies DF3 and B72. 3 in Reactivity to Breast Cancer

  • Noriaki Ohuchi
  • Minoru Akimoto
  • Shozo Mori
  • Donald W. Kufe
  • Jeffrey Schlom

Abstract

Monoclonal antibodies (MAbs) developed thus far against human carcinomas have led to a more systemic study of human breast tumors. The reactive antigens include a wide variety of cellular products such as receptors, oncogene products, and tumor-associated antigens (TAAs) which can be utilized to “fingerprint” cell populations. The utilization of antibodies as immunologic probes to detect and phenotype cell populations in tissue preparations have moved rapidly from the research area to the clinical application. The MAbs are also increasingly being utilized in serum assays to detect circulating TAAs in patients with breast carcinoma.

Keywords

Breast Carcinoma Benign Breast Disease Intraductal Papilloma High Molecular Weight Glycoprotein Recurrent Breast Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. W. Kufe, G. Inghirami, M. Abe, D. Hayes, H. Justi-Wheeler, and J. Schlom, Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    H. Sekine, T. Ohno, and D. W. Kufe, Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J. Immunol. 135;3610 (1985).PubMedGoogle Scholar
  3. 3.
    E. L. Friedman, D. F. Hayes, and D. W. Kufe, Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res. 46:5189 (1986).PubMedGoogle Scholar
  4. 4.
    M. Abe, and D. W. Kufe, Identification of a family of high molecular weight tumor-associated glycoproteins. J. Immunol. 139:257 (1987).PubMedGoogle Scholar
  5. 5.
    N. Ohuchi, D. L. Page, M. J. Merino, M. J. Viglione, D. W. Kufe, and J. Schlom, Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. J. Natl. Cancer Inst.79:109 (1987).PubMedGoogle Scholar
  6. 6.
    D. F. Hayes, H. Sekine, T. Ohno, M. Abe, K. Keefe, and D. W. Kufe, Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J. Clin. Invest. 75:1671 (1985).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Tobias, C. Rothwell, J. Wagner, A. Green, and Y. S. Liu, Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D-8/DF3. J. Am. Assoc. Clin. Chem. 31:986 (1985).Google Scholar
  8. 8.
    A. van Dalen, J. M. G. Bonfrer, H. Dupree, K. H. Heering, D. L. van der Linde, and W. J. Nooijen, CA15–3 as a marker in the follow-up of patients with breast cancer, in: “Tumor marker” G. Wust, ed. , Steinkopff Verlag, Darmstadt, Germany, pp. 182 (1987).Google Scholar
  9. 9.
    J. Hilkens, F. Buijs, J. Higers, Ph. Hageman, J. Calafat, A. Sonnenberg, and M. van der Valk, Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer 34: 197 (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    D. F. Hayes, V. R. Jr. Zurawski, and D. W. Kufe, Comparison of circulating CA15–3 and carcinoembryonic antigen levels in patients with breast cancer. J. Clin. Oncol. 4:1542 (1986).PubMedGoogle Scholar
  11. 11.
    D. Colcher, P. Horan Hand, M. Nuti, and J. Schlom, A spectrum of monoclonal antibodies rective with human mammary tumor cells. Proc. Natl. Acad. Sci. USA 78;3199 (1981).PubMedCrossRefGoogle Scholar
  12. 12.
    V. G. Johnson, J. Schlom, A. J. Paterson, J. Bennet, J. L. Magnani, and D. Colcher, Analysis of a human tumor-associated glycoprotein (TAG-72) identified by a monoclonal antibody B72. 3. Cancer Res. 46:850 (1986).PubMedGoogle Scholar
  13. 13.
    A. Thor, N. Ohuchi, C. A. Szpak, W. W. Johnston, and J. Schlom, Distribution of oncofetal antigen tumor-associated glycoprotein (TAG-72) identified by a monoclonal antibody B72. 3. Cancer Res. 46:3118 (1986).PubMedGoogle Scholar
  14. 14.
    N. Ohuchi, A. Thor. M. Nose, M. Kyogoku, and J. Schlom, Tumorassociated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. Int. J. Cancer 38:643 (1986).PubMedCrossRefGoogle Scholar
  15. 15.
    A. Thar, F. Gorstein, N. Ohuchi, C. A. Szpak, W. W. Johnson, and J. Schlom, Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72. 3. J. Natl. Cancer Inst. 76:995 (1986).Google Scholar
  16. 16.
    W. W. Johnston, C. A. Szpak, A. Thor, and J. Schlom, Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72. 3. Cancer Res. 46:6462 (1986).PubMedGoogle Scholar
  17. 17.
    A. Thor, M. J. Viglione, R. Muraro, N. Ohuchi, J. Schlom, and F. Gorstein, Monoclonal antibody B72. 3 reactivity with human endometrium: a study of normal and malignant tissues. Int. J. Gynecol. Pathol. 6 : 235 (1987).PubMedCrossRefGoogle Scholar
  18. 18.
    R. Muraro, M. Kuroki, D. Wunderlich, D. J. Poole, D. Colcher, A. Thor, J. W. Greiner, J. Simpson, A. Molinoto, P. Noguchi, and J. Scholom, Generation and characterization of B72. 3 second generation monoclonal antibodies reactive with the tumorassociated glycoprotein 72 antigen. Cancer Res. 48:4588 (1988).PubMedGoogle Scholar
  19. 19.
    N. Ohuchi, J. F. Simpson, D. Colcher, and J. Schlom, Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int. J. Cancer 40:726 (1987).PubMedCrossRefGoogle Scholar
  20. 20.
    M. S. Lan, R. C. Bast, M. I. Colnagi, R. C. Knapp, D. Colcher, J. Schlom, and R. S. Metzgar, Co-expression of human cancerassociated epitopes on mucin molecules. Int. J. Cancer 39:68 (1986).CrossRefGoogle Scholar
  21. 21.
    N. Ohuchi, S. Mori, E. Gero, D. Colcher, F. Mochizuki, T. Nishihira, K. Hirayama, N. Matoba, P. M. Kaplan, and J. Schlom, Serum levels of tumor-associated glycoprotein (TAG-72) in patients with carcinoma detected by CA72–4 radioimmunometric assay. (submitted for publication)Google Scholar
  22. 22.
    N. Ohuchi, Y. Taira, K. Takahashi, S. Sato, H. Matoba, M. Akimoto, and S. Mori, Comparison of serum levels of CA15–3 and cytoplasmic reactivity of monoclonal antibody DF3 in patients with breast cancer. (submitted for publication).Google Scholar
  23. 23.
    J. P. Sloane, and M. G. Ormerod, Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer 17:1786 (1981).CrossRefGoogle Scholar
  24. 24.
    J. Taylor-Papadimitriou, J. A. Peterson, J. Arklie, J. Burchell, R. L. Ceriani, and W. F. Bodmer, Monoclonal antibodies to epithelium specific components of the milk fat globule membrane: production and reaction with cells. Int. J. Cancer 28:17 (1981).PubMedCrossRefGoogle Scholar
  25. 25.
    R. L. Ceriani, J. A. Peterson, J. Y. Lee, R. Moncada, and E. W. Blank, Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule. Somatic Cell Genet. 9:415 (1983).PubMedCrossRefGoogle Scholar
  26. 26.
    A. Thor, M. J. Viglione, N. Ohuchi, J. F. Simpson, R. Steis, J. Cousar, M. Lippman, D. W. Kufe, and J. Schlom, Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Breast Cancer Res. Treat. 11 :133 (1988).PubMedCrossRefGoogle Scholar
  27. 27.
    L. D. Papsidero, G. A. Croghan, M. J. O’Connell, L. A. Vallenzuella, T. Nemoto, and T. M. Chu, Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma. Cancer Res. 43:1741 (1983).PubMedGoogle Scholar
  28. 28.
    N. Ohuchi, D. Wunderlich, J. Fujita, D. Colcher, R. Muraro, M. Nose, and J. Schlom, Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes. Cancer Res. 47:3565 (1987).PubMedGoogle Scholar
  29. 29.
    P. Horan Hand, D. Colcher, D. Salomon, J. Ridge, P. Noguchi, and J. Schlom, Influence of spatial configulation of carcinoma cell populations in the expression of a tumor-associated glycoprotein. Cancer Res. 45. 833 (1985).Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Noriaki Ohuchi
    • 1
  • Minoru Akimoto
    • 1
  • Shozo Mori
    • 1
  • Donald W. Kufe
    • 2
  • Jeffrey Schlom
    • 3
  1. 1.Second Department of SurgeryTohoku University School of MedicineSendai 980Japan
  2. 2.Dana-Farber Cancer InstituteBostonUSA
  3. 3.Laboratory of Tumor Immunology and BiologyNCI, NIHUSA

Personalised recommendations